Bisphosphonate Treatment and Related Agents in Children - Osteogenesis Imperfecta - page 461

[4] Russell RG. Bisphosphonates: mode of action and pharmacol-
ogy. Pediatrics 2007;119(Suppl 2):S150-62.
[5] Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G,
Travers R. Cyclic administration of pamidronate in children with
severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
[6] Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet
2004;363:1377-85.
[7] Astrom E, Soderhall S. Beneicial effect of long term intravenous
bisphosphonate treatment of osteogenesis imperfecta. Arch Dis
Child 2002;86:356-64.
[8] Astrom E, Magnusson P, Eksborg S, Soderhall S. Biochemical
bone markers in the assessment and pamidronate treatment of
children and adolescents with osteogenesis imperfecta. Acta
Paediatr 2010;99:1834-40.
[9] Choi JH, Shin YL, Yoo HW. Short-term eficacy of monthly
pamidronate infusion in patients with osteogenesis imperfecta.
J Korean Med Sci 2007;22:209-12.

[22] Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F,

Eryilmaz SK, et al. Successful results of pamidronate treatment
in children with osteogenesis imperfecta with emphasis on
the interpretation of bone mineral density for local standards.
J Pediatr Orthop 2008;28:483-7.

[23] Vallo A, Rodriguez-Leyva F, Rodriguez Soriano J. Osteogenesis

imperfecta: anthropometric, skeletal and mineral metabolic
effects of long-term intravenous pamidronate therapy. Acta
Paediatr 2006;95:332-9.

[24] Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of

intravenous pamidronate on the bone tissue of children
and adolescents with osteogenesis imperfecta. J Clin Invest
2002;110:1293-9.

[25] Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphy-

seal lines in a child treated with pamidronate: histomorphomet-
ric analysis. J Bone Miner Res 2004;19:1191-3.

[26] Sarraf KM. Images in clinical medicine. Radiographic zebra

lines from cyclical pamidronate therapy. N Engl J Med
2011;365:e5.

[10] Rush ET, DeHaai K, Kreikemeier RM, Lutz RE. Evaluation

and comparison of safety, convenience and cost of administer-
ing intravenous pamidronate infusions to children in the home
and ambulatory care settings. J Pediatr Endocrinol Metab
2012;25:493-7.

[27] Suresh S, Thomas JK. Metaphyseal bands in osteogenesis imper-

fecta. Indian J Radiol Imaging 2010;20:42-4.

[28] Vinson EN. Clinical image: pamidronate “zebra” lines. Arthritis

Rheum 2008;58:2817. [11] Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH.

Osteogenesis imperfecta types I, III, and IV: effect of pami-
dronate therapy on bone and mineral metabolism. J Clin
Endocrinol Metab 2003;88:986-92.

[29] Damiani D. Metaphyseal sclerosis associated with bisphospho-

nate therapy. J Pediatr Endocrinol Metab 2007;20:1167.

[30] Onwuneme C, Abdalla K, Cassidy N, Hensey O, Ryan S.

Radiological indings in cyclical administration of intravenous
pamidronate in children with osteoporosis. Arch Dis Child
2007;92:1087.

[12] Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous

pamidronate treatment in children with moderate to severe
osteogenesis imperfecta: assessment of indices of dual-energy
X-ray absorptiometry and bone metabolic markers during the
irst year of therapy. Bone 2004;34:539-46.

[31] Srinivasan R. Pamidronate lines. Indian Pediatr 2005;42:959-60.

[32] Davies JH, Gregory JW. Radiographic long bone appearance

in a child administered cyclical pamidronate. Arch Dis Child
2003;88:854.

[13] Cabral de Menezes Filho H, Rodrigues JM, Radonsky V, Della

Manna T, Kuperman H, Steinmetz L, et al. Decrease of serum
alkaline phosphatase after three cycles of pamidronate diso-
dium in children with severe osteogenesis imperfecta. Horm
Res 2007;68(Suppl 5):207-8.

[33] Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral

morphometry in children and adolescents with osteogenesis
imperfecta: effect of intravenous pamidronate treatment. Bone
2006;39:901-6. [14] Lowing K, Astrom E, Oscarsson KA, Soderhall S, Eliasson AC.

Effect of intravenous pamidronate therapy on everyday activi-
ties in children with osteogenesis imperfecta. Acta Paediatr
2007;96:1180-3.

[34] Semler O, Beccard R, Palmisano D, Demant A, Fricke O,

Schoenau E, et al. Reshaping of vertebrae during treatment
with neridronate or pamidronate in children with osteogenesis
imperfecta. Horm Res Paediatr 2011;76:321-7. [15] Salehpour S, Tavakkoli S. Cyclic pamidronate therapy in chil-

dren with osteogenesis imperfecta. J Pediatr Endocrinol Metab
2010;23:73-80.

[35] Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE,

Chernoff EJ, et al. Controlled trial of pamidronate in children
with types III and IV osteogenesis imperfecta conirms vertebral
gains but not short-term functional improvement. J Bone Miner
Res 2005;20:977-86.

[16] Bhadada SK, Santosh R, Bhansali A, Upreti V, Dutta P.

Osteogenesis imperfecta. J Assoc Physicians India 2009;57:33-6.

[17] Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N,

Yordam N. Cyclic pamidronate therapy in children with osteo-
genesis imperfecta: results of treatment and follow-up after dis-
continuation. J Pediatr Endocrinol Metab 2008;21:63-72.

[36] Hasegawa K, Inoue M, Seino Y, Morishima T, Tanaka H. Growth

of infants with osteogenesis imperfecta treated with bisphos-
phonate. Pediatr Int 2009;51:54-8.

[18] Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C.

Beneits of pamidronate in children with osteogenesis imper-
fecta: an open prospective study. Joint Bone Spine 2005;72:313-8.

[37] Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight

development during four years of therapy with cyclical intrave-
nous pamidronate in children and adolescents with osteogen-
esis imperfecta types I, III, and IV. Pediatrics 2003;111:1030-6. [19] Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and

density in children and adolescents with osteogenesis imper-
fecta: effect of intravenous pamidronate therapy. J Bone Miner
Res 2003;18:610-4.

[38] Heino TJ, Astrom E, Laurencikas E, Savendahl L, Soderhall S.

Intravenous pamidronate treatment improves growth in pre-
pubertal osteogenesis imperfecta patients. Horm Res Paediatr
2011;75:354-61. [20] Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone

changes after pamidronate discontinuation in children and ado-
lescents with osteogenesis imperfecta. Bone 2007;40:821-7.

[39] Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S,

Rabzel M, et al. Rapid increase in grip force after start of
pamidronate therapy in children and adolescents with severe
osteogenesis imperfecta. Pediatrics 2003;111:E601-3.

[21] Bajpai A, Kabra M, Gupta N, Sharda S, Ghosh M. Intravenous

pamidronate therapy in osteogenesis imperfecta: response to
treatment and factors inluencing outcome. J Pediatr Orthop
2007;27:225-7.

[40] Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect

of intravenous pamidronate therapy on functional abilities and